CA 15-3 Serum Levels in Ovarian Cancer
- 1 January 1988
- journal article
- research article
- Published by S. Karger AG in Oncology
- Vol. 45 (3) , 263-267
- https://doi.org/10.1159/000226575
Abstract
Serum levels of CA 15-3, an antigen expressed by human breast carcinoma cells, were measured in 58 ovarian cancer patients, 24 patients with benign ovarian tumor and 62 patients with benign gynecological conditions. Abnormally high serum CA 15-3 levels were found in 41 of 58 patients (71 %) with ovarian cancer. The percentage of CA 15-3 positivity correlated with tumor stage. Elevated serum CA 15-3 levels were found in 5 of 24 patients (20%) with benign ovarian tumor. None of the patients with benign gynecological conditions had increased serum CA 15-3 levels. Serial measurements showed CA 15-3 concentrations to be correlated with the clinical behavior of disease in 21 of 25 patients (84%). CA 15-3 serum levels were also found to be correlated with findings on second look. These results suggest that CA 15-3 may represent a useful tumor marker in ovarian cancer.Keywords
This publication has 12 references indexed in Scilit:
- MAM-6 ANTIGEN, A NEW SERUM MARKER FOR BREAST-CANCER MONITORING1986
- ROLE OF CA-125 AS TUMOR-MARKER IN OVARIAN-CARCINOMA1986
- PREOPERATIVE EVALUATION OF SERUM CA-125 LEVELS IN PATIENTS WITH PRIMARY EPITHELIAL OVARIAN-CANCER1986
- Biochemical and immunohistochemical studies on carcinoembryonic antigen of ovarian mucinous and serous tumorsGynecologic Oncology, 1986
- Tumour‐associated antigen CA 125 in patients with ovarian cancerBJOG: An International Journal of Obstetrics and Gynaecology, 1985
- Predictive value of CA 125 antigen levels in second-look procedures for ovarian cancerAmerican Journal of Obstetrics and Gynecology, 1985
- Monitoring human ovarian carcinoma with a combination of CA 125, CA 19-9, and carcinoembryonic antigenAmerican Journal of Obstetrics and Gynecology, 1984
- CA125-ANTIGEN LEVELS IN OBSTETRIC AND GYNECOLOGIC PATIENTS1984
- Differential Reactivity of a Novel Monoclonal Antibody (DF3) with Human Malignant versus Benign Breast TumorsHybridoma, 1984
- A Radioimmunoassay Using a Monoclonal Antibody to Monitor the Course of Epithelial Ovarian CancerNew England Journal of Medicine, 1983